Loading...
•
Dec 31, 2023
InspireMD Q4 2023 Earnings Report
InspireMD reported record revenue, driven by CE Mark recertification and increased stent sales. Clinical trial data showed favorable results, and the company advanced its product pipeline.
Key Takeaways
InspireMD reported a record fourth quarter with a 71.6% increase in revenue compared to the same period last year. The company's growth was driven by CE Mark recertification and increased stent sales. InspireMD also announced positive data from its C-GUARDIANS clinical trial and advancements in its product pipeline.
Total revenue increased by 71.6% to $1.761 million compared to Q4 2022.
Over 3,100 stents were sold, representing a 74% year-over-year increase.
Gross profit increased by 155.1% to $505,000 compared to Q4 2022.
Cash, cash equivalents, short-term bank deposits and marketable securities were $39.0 million as of December 31, 2023, compared to $17.8 million as of December 31, 2022.
InspireMD
InspireMD
InspireMD Revenue by Segment
Revenue by Segment
CGuard EPS Revenue
CapyFin.com Forward Guidance
InspireMD is positioned with solutions to support CAS and TCAR procedures, with clinical and regulatory catalysts expected this year and next.